Alcohol Addiction – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Alcohol Addiction – Pipeline Review, H1 2017’, provides an overview of the Alcohol Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction

The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects

The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Alcohol Addiction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

Adial Pharmaceuticals LLC

Astraea Therapeutics LLC

BioCorRx Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Curemark LLC

Eli Lilly and Company

Ethypharm SA

Euthymics Bioscience Inc

H. Lundbeck A/S

Heptares Therapeutics Ltd

Indivior Plc

Kinnov Therapeutics SAS

Kyorin Pharmaceutical Co Ltd

Lohocla Research Corp

Omeros Corp

Pfizer Inc

Savant HWP Inc

SK Biopharmaceuticals Co Ltd

Tonix Pharmaceuticals Holding Corp

VM Discovery Inc

XenoPort Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alcohol Addiction - Overview

Alcohol Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcohol Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcohol Addiction - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Adial Pharmaceuticals LLC

Astraea Therapeutics LLC

BioCorRx Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Curemark LLC

Eli Lilly and Company

Ethypharm SA

Euthymics Bioscience Inc

H. Lundbeck A/S

Heptares Therapeutics Ltd

Indivior Plc

Kinnov Therapeutics SAS

Kyorin Pharmaceutical Co Ltd

Lohocla Research Corp

Omeros Corp

Pfizer Inc

Savant HWP Inc

SK Biopharmaceuticals Co Ltd

Tonix Pharmaceuticals Holding Corp

VM Discovery Inc

XenoPort Inc

Zynerba Pharmaceuticals Inc

Alcohol Addiction - Drug Profiles

(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(disulfiram + selegiline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-705253 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABT-436 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amitifadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen placarbil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baclofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carisbamate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-1212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gabapentin enacarbil ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDTic - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

odelepran hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05190457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-10406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcohol Addiction - Dormant Projects

Alcohol Addiction - Discontinued Products

Alcohol Addiction - Product Development Milestones

Featured News & Press Releases

Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence

Nov 28, 2016: BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA

Sep 15, 2016: BioCorRx Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product

Sep 03, 2016: Baclofen helps reduce the consumption of alcohol in alcohol - dependent patients

Aug 31, 2016: BioCorRx Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology

Jul 25, 2016: Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder

Jul 20, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health

Jul 14, 2016: BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant

Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

Jan 14, 2016: BioCorRx Announces New Agreements With Wellness Centers in Slidell, LA, Memphis and Nashville, TN, and Philadelphia, PA

Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501

Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting

Dec 07, 2015: BioCorRx Announces Agreements With Additional Wellness Centers in California, Wisconsin and Arizona

Oct 13, 2015: Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Alcohol Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Alcohol Addiction – Pipeline by AbbVie Inc, H1 2017

Alcohol Addiction – Pipeline by Addex Therapeutics Ltd, H1 2017

Alcohol Addiction – Pipeline by Adial Pharmaceuticals LLC, H1 2017

Alcohol Addiction – Pipeline by Astraea Therapeutics LLC, H1 2017

Alcohol Addiction – Pipeline by BioCorRx Inc, H1 2017

Alcohol Addiction – Pipeline by Bionex Pharmaceuticals LLC, H1 2017

Alcohol Addiction – Pipeline by Bioprojet SCR, H1 2017

Alcohol Addiction – Pipeline by Cerecor Inc, H1 2017

Alcohol Addiction – Pipeline by Chronos Therapeutics Ltd, H1 2017

Alcohol Addiction – Pipeline by Corcept Therapeutics Inc, H1 2017

Alcohol Addiction – Pipeline by Curemark LLC, H1 2017

Alcohol Addiction – Pipeline by Eli Lilly and Company, H1 2017

Alcohol Addiction – Pipeline by Ethypharm SA, H1 2017

Alcohol Addiction – Pipeline by Euthymics Bioscience Inc, H1 2017

Alcohol Addiction – Pipeline by H. Lundbeck A/S, H1 2017

Alcohol Addiction – Pipeline by Heptares Therapeutics Ltd, H1 2017

Alcohol Addiction – Pipeline by Indivior Plc, H1 2017

Alcohol Addiction – Pipeline by Kinnov Therapeutics SAS, H1 2017

Alcohol Addiction – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Alcohol Addiction – Pipeline by Lohocla Research Corp, H1 2017

Alcohol Addiction – Pipeline by Omeros Corp, H1 2017

Alcohol Addiction – Pipeline by Pfizer Inc, H1 2017

Alcohol Addiction – Pipeline by Savant HWP Inc, H1 2017

Alcohol Addiction – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Alcohol Addiction – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017

Alcohol Addiction – Pipeline by VM Discovery Inc, H1 2017

Alcohol Addiction – Pipeline by XenoPort Inc, H1 2017

Alcohol Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Alcohol Addiction – Dormant Projects, H1 2017

Alcohol Addiction – Dormant Projects, H1 2017 (Contd..1), H1 2017

Alcohol Addiction – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Alcohol Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports